局部用藥市場－全球產業規模、佔有率、趨勢、機會和預測：按產品、給藥途徑、最終用戶、地區和競爭格局分類，2021-2031年

全球局部用藥市場預計將從 2025 年的 2,481.1 億美元成長到 2031 年的 4,195.5 億美元，複合年成長率為 9.15%。

這種給藥方式是將藥物直接輸送到黏膜或皮膚，以在標靶發揮治療作用，同時最大限度地減少全身吸收。市場成長主要受慢性病和皮膚病患病率上升以及對非侵入性和易用性治療方法日益成長的需求所驅動。經皮吸收貼片、乳膏和凝膠等製劑技術的進步也推動了這一成長趨勢。歐洲製藥企業聯合會 (EFPIA) 強調了該領域對創新的投入，並報告稱，預計到 2024 年，歐洲製藥業在研發主導的投資將達到 550 億歐元。另一方面，皮膚的天然屏障限制了許多治療物質的吸收效率，這是市場成長的主要障礙。克服這項生物學限制、提高滲透性並確保可靠的藥物遞送需要複雜的製劑技術，這對製藥公司而言是一項重大的研發挑戰。

市場促進因素

全球局部用藥市場的主要驅動力是慢性病和皮膚病患病率的不斷上升。相當一部分人飽受痤瘡、乾癬和濕疹等疾病的困擾，因此迫切需要便捷有效的治療方法。局部用藥可以直接作用於患處，有助於減輕注射和口服藥物常見的全身性副作用。美國國家健康統計中心在2026年1月發布的報告進一步印證了這些問題的普遍性：到2024年，美國成年人中將有7.7%被診斷出患有濕疹。濕疹發生率的上升持續推高了對各種局部用藥的需求，從而促進了市場擴張。此外，製劑技術的進步圖透過提高患者依從性、增強療效和擴大可治療疾病的範圍，加速了市場成長。經皮吸收貼片、微乳劑和奈米技術的進步，能夠提高藥物吸收率、控制釋放並減少皮膚刺激。例如，Drug Hunter在2025年1月報道稱，一種開創性的局部氧化氮釋放劑verdazimer（Zelsuvmi）於2024年獲得FDA核准，用於治療傳染性軟疣，這便是這些新型製劑強大功效的一個例證。此類技術飛躍正推動著以患者為中心的先進局部治療方案的研發。這波創新浪潮得到了充足的資金支持，根據摩根大通發布的《2024年生物製藥產業洞察報告》，2024年生物製藥領域的投資將達到260億美元。持續的資金投入凸顯了製藥業致力於開發尖端藥物遞送方法的決心。

市場挑戰

皮膚的天然保護屏障對全球局部給藥市場構成重大挑戰。這種生物學限制直接限制了多種治療藥物的有效吸收，因此需要進行大量的研發工作，以開發能夠提高滲透性並確保藥物穩定釋放的個人化製劑。建構這些複雜的機制，包括先進的經皮吸收貼片、乳霜和凝膠，會顯著增加產品開發和監管核准所需的時間和資金。對製藥公司而言，這些日益嚴峻的挑戰導致研發週期延長、成本增加，最終延緩新型經皮療法的上市。根據國際藥品製造商協會聯合會（IFPMA）預測，到2025年，排名前50名的製藥公司每年在研發方面的支出預計將超過2,000億美元。其中相當一部分資金用於克服基本的給藥障礙，導致創新步伐放緩，市場成長受限。

市場趨勢

市場關鍵趨勢之一是將治療應用拓展到非皮膚科領域，從傳統的皮膚疾病治療擴展到更廣泛的系統性疾病治療。這項轉變充分利用了經皮和局部給藥的優勢——即提高患者用藥便利性並減少全身暴露——並應用於神經系統疾病、荷爾蒙補充療法和疼痛緩解等領域。透過提供實用且非侵入性的替代傳統注射和口服藥物的方案，這項策略正在顯著擴大市場範圍。為了反映這一向疼痛管理領域的轉變，Innocan Pharma Corporation Ltd. 於 2025 年 5 月宣布，已在墨西哥獲得一項基於大麻的局部鎮痛劑專利。此外，智慧互聯給藥機制的引入是另一個關鍵趨勢，它正在將局部用藥的給藥方式從被動過程轉變為主動智慧管理系統。透過整合互聯、數據分析和感測器，這些先進設備能夠即時追蹤生理指標，改善患者用藥依從性的監測，並允許動態調整藥物釋放速率。這些技術進步將推動遠距醫療框架和個人化醫療的轉型，最終提高治療的反應速度和準確性。為了體現這一進展，美國醫療保險和醫療補助服務中心 (CMS) 於 2026 年 1 月宣布，將於 2026 年 7 月推出「ACCESS 模式」。該模式旨在獎勵那些在慢性病管理（包括藥物管理相關疾病）中採用技術主導服務的聯邦醫療保險 B 部分醫療保健專業人員。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球局部用藥市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 產品類別（半固態劑型、液體劑型、固態劑型、經皮劑型）
  • 給藥途徑（經皮給藥、眼部給藥、直腸給藥、鼻腔給藥）
  • 按最終使用者（醫院、診所、家庭醫療保健、診斷中心等）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美局部用藥市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲局部用藥市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區局部用藥市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲局部用藥市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲局部用藥市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章 全球局部給藥市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Johnson & Johnson Services Inc.
• Nestle SA
• GlaxoSmithKline Plc
• Novartis AG
• Merck & Co. Inc.
• Crescita Therapeutics Inc.
• Cipla Ltd.
• Taro Pharmaceutical Industries Ltd.
• Valeant Pharmaceuticals International Inc.
• Glenmark Pharmaceuticals Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Topical Drug Delivery Market is projected to grow from USD 248.11 Billion in 2025 to USD 419.55 Billion by 2031 at a 9.15% CAGR. This delivery method entails administering medications straight to mucous membranes or the skin to produce targeted therapeutic results while limiting systemic absorption. Market growth is heavily fueled by the rising frequency of chronic illnesses and skin conditions, alongside a surging preference for non-invasive, easy-to-use therapies. Progress in formulation methods, such as transdermal patches, creams, and gels, also bolsters this upward trajectory. Highlighting the sector's commitment to innovation, the European Federation of Pharmaceutical Industries and Associations reported an estimated €55,000 million investment in research and development by Europe's research-centric pharmaceutical industry in 2024. Conversely, a major obstacle hindering market growth is the natural barrier of the skin, which limits how effectively numerous therapeutic substances can be absorbed. This biological constraint requires intricate formulation techniques to improve permeability and guarantee reliable drug administration, creating substantial developmental challenges for pharmaceutical firms.

Market Driver

The Global topical drug delivery market is primarily propelled by the growing frequency of chronic illnesses and dermatological disorders. A large segment of the population suffers from conditions like acne, psoriasis, and eczema, creating a strong need for accessible and potent therapies. By allowing direct administration to the target site, topical treatments help reduce the systemic adverse effects frequently linked to injectable or oral drugs. Highlighting the prevalence of these issues, the National Center for Health Statistics noted in January 2026 that 7.7% of US adults had an eczema diagnosis in 2024. This escalating occurrence drives consistent demand for various topical therapies, thereby boosting market expansion. Furthermore, breakthroughs in drug formulation techniques accelerate market growth by improving patient adherence, boosting effectiveness, and broadening the scope of treatable ailments. Developments in transdermal patches, microemulsions, and nanotechnology facilitate better drug absorption, regulated release, and minimized skin irritation. Illustrating the power of these new formulations, Drug Hunter reported in January 2025 that berdazimer (Zelsuvmi), a pioneering topical nitric oxide-releasing medication, earned FDA approval in 2024 for molluscum contagiosum treatment. Such technological leaps encourage the creation of highly advanced, patient-centric topical solutions. This atmosphere of innovation is heavily backed by financial resources, with J.P. Morgan's 2024 Biopharma Industry Insights indicating that biopharma venture investments hit USD 26.0 billion in 2024. This continuous funding underscores the pharmaceutical sector's dedication to developing cutting-edge delivery methods.

Market Challenge

The skin's natural protective barrier presents a major obstacle to the global topical drug delivery market. By directly limiting the efficient absorption of numerous therapeutic agents, this biological restriction necessitates extensive research and development to create tailored formulations capable of improving permeability and ensuring steady medication delivery. Creating these intricate mechanisms, which include sophisticated transdermal patches, creams, and gels, drastically raises both the time and financial commitments required for product creation and regulatory clearance. For pharmaceutical businesses, these elevated obstacles translate into extended development timelines and escalating expenses, ultimately delaying the launch of novel topical therapies. As projected by the International Federation of Pharmaceutical Manufacturers and Associations, the top 50 pharmaceutical firms were anticipated to spend over USD 200 billion annually on research and development by 2025. A significant share of this funding is directed toward overcoming foundational delivery obstacles, which consequently slows the pace of innovation and restricts market growth.

Market Trends

A major trend in the market is the expansion into non-dermatological therapeutic uses, moving past conventional skin diseases to treat a broader range of systemic issues. This transition leverages the advantages of transdermal and topical administration, namely heightened patient convenience and lowered systemic exposure, for applications including neurological ailments, hormone replacement, and pain relief. By offering a practical, non-invasive substitute for traditional injections or oral pills, this strategy significantly widens the market's scope. Highlighting this shift into pain management, Innocan Pharma Corporation Ltd. reported securing a Mexican patent for a topical cannabis-based pain relief medication in May 2025. Additionally, the incorporation of smart, connected delivery mechanisms is a vital trend shifting topical drug administration from a passive process to an active, intelligently managed system. By embedding connectivity, data analytics, and sensors, these sophisticated devices facilitate the real-time tracking of physiological metrics, improve patient compliance monitoring, and allow for the dynamic modification of drug release rates. These technological strides bolster the shift toward remote healthcare frameworks and personalized medicine, ultimately enhancing treatment responsiveness and accuracy. Reflecting this progression, the Centers for Medicare and Medicaid Services declared in January 2026 the impending July 2026 launch of its ACCESS Model, designed to reward Medicare Part B practitioners who employ technology-driven services to manage chronic diseases, encompassing those related to medication delivery.

Key Market Players

• Johnson & Johnson Services Inc.
• Nestle SA
• GlaxoSmithKline Plc
• Novartis AG
• Merck & Co. Inc.
• Crescita Therapeutics Inc.
• Cipla Ltd.
• Taro Pharmaceutical Industries Ltd.
• Valeant Pharmaceuticals International Inc.
• Glenmark Pharmaceuticals Ltd

Report Scope

In this report, the Global Topical Drug Delivery Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Topical Drug Delivery Market , By Product

• Semi-Solid Formulations
• Liquid Formulations
• Solid Formulations
• Transdermal Products

Topical Drug Delivery Market , By Route of Administration

• Dermal Drug Delivery
• Ophthalmic Drug Delivery
• Rectal Drug Delivery
• Nasal Drug Delivery

Topical Drug Delivery Market , By End-User

• Hospitals
• Clinics
• Home Healthcare
• Diagnostic Centers
• Others

Topical Drug Delivery Market , By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Topical Drug Delivery Market .

Available Customizations:

Global Topical Drug Delivery Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Topical Drug Delivery Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Semi-Solid Formulations, Liquid Formulations, Solid Formulations, Transdermal Products)
  • 5.2.2. By Route of Administration (Dermal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery, Nasal Drug Delivery)
  • 5.2.3. By End-User (Hospitals, Clinics, Home Healthcare, Diagnostic Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Topical Drug Delivery Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Route of Administration
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Topical Drug Delivery Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By End-User
  • 6.3.2. Canada Topical Drug Delivery Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By End-User
  • 6.3.3. Mexico Topical Drug Delivery Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By End-User

7. Europe Topical Drug Delivery Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Route of Administration
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Topical Drug Delivery Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By End-User
  • 7.3.2. France Topical Drug Delivery Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By End-User
  • 7.3.3. United Kingdom Topical Drug Delivery Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By End-User
  • 7.3.4. Italy Topical Drug Delivery Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By End-User
  • 7.3.5. Spain Topical Drug Delivery Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By End-User

8. Asia Pacific Topical Drug Delivery Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Route of Administration
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Topical Drug Delivery Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By End-User
  • 8.3.2. India Topical Drug Delivery Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By End-User
  • 8.3.3. Japan Topical Drug Delivery Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By End-User
  • 8.3.4. South Korea Topical Drug Delivery Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By End-User
  • 8.3.5. Australia Topical Drug Delivery Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By End-User

9. Middle East & Africa Topical Drug Delivery Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Route of Administration
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Topical Drug Delivery Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By End-User
  • 9.3.2. UAE Topical Drug Delivery Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By End-User
  • 9.3.3. South Africa Topical Drug Delivery Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By End-User

10. South America Topical Drug Delivery Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Route of Administration
  • 10.2.3. By End-User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Topical Drug Delivery Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By End-User
  • 10.3.2. Colombia Topical Drug Delivery Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By End-User
  • 10.3.3. Argentina Topical Drug Delivery Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Topical Drug Delivery Market : SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Johnson & Johnson Services Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Nestle SA
• 15.3. GlaxoSmithKline Plc
• 15.4. Novartis AG
• 15.5. Merck & Co. Inc.
• 15.6. Crescita Therapeutics Inc.
• 15.7. Cipla Ltd.
• 15.8. Taro Pharmaceutical Industries Ltd.
• 15.9. Valeant Pharmaceuticals International Inc.
• 15.10. Glenmark Pharmaceuticals Ltd

16. Strategic Recommendations

17. About Us & Disclaimer